PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33542419-1	2021	Soil available phosphorus (SAP) and soil available potassium (SAK) are important elements in the growth of plants.	Potassium	51-60	polo like kinase 4	Homo sapiens	62-65
33706192-5	2021	The Wnt/beta-catenin signaling antagonist Dickkopf 1 (DKK1) or the BMP-Smads antagonist LDN193189 dramatically suppressed hBMSC osteoblast differentiation, and partially attenuated the promotive effects of PLK4 knockdown on hBMSC osteogenic differentiation.	LDN 193189	88-97	polo like kinase 4	Homo sapiens	206-210
33293764-3	2020	Here, to investigate whether radiation-induced abnormal centrosome amplification is essential for induction of radiation-induced mitotic catastrophe, centrinone-B, a highly selective inhibitor of polo-like kinase 4, was utilized to inhibit centrosome amplification, since polo-like kinase 4 is an essential kinase in centrosome duplication.	centrinone-B	150-162	polo like kinase 4	Homo sapiens	196-214
33171265-11	2021	These observations highlight the urgent need to develop highly specific ATP-competitive inhibitors for PLK4 and for PLK1 like the 3rd generation PLK-inhibitor Onvansertib to prevent the inhibition of tumor-suppressor PLKs in- and outside of mitosis.	Adenosine Triphosphate	72-75	polo like kinase 4	Homo sapiens	103-107
33293764-3	2020	Here, to investigate whether radiation-induced abnormal centrosome amplification is essential for induction of radiation-induced mitotic catastrophe, centrinone-B, a highly selective inhibitor of polo-like kinase 4, was utilized to inhibit centrosome amplification, since polo-like kinase 4 is an essential kinase in centrosome duplication.	centrinone-B	150-162	polo like kinase 4	Homo sapiens	272-290
32884289-0	2020	MiR-654-3p Suppresses Non-Small Cell Lung Cancer Tumourigenesis by Inhibiting PLK4.	mir-654-3p	0-10	polo like kinase 4	Homo sapiens	78-82
33171067-2	2020	Plk4 phosphorylates a single serine residue at the N-terminus of Ana2 to promote Ana2"s loading to the site of procentriole formation.	Serine	29-35	polo like kinase 4	Homo sapiens	0-4
33171067-2	2020	Plk4 phosphorylates a single serine residue at the N-terminus of Ana2 to promote Ana2"s loading to the site of procentriole formation.	ana2	65-69	polo like kinase 4	Homo sapiens	0-4
33171067-2	2020	Plk4 phosphorylates a single serine residue at the N-terminus of Ana2 to promote Ana2"s loading to the site of procentriole formation.	ana2	81-85	polo like kinase 4	Homo sapiens	0-4
33171067-3	2020	Four conserved serines in Ana2"s STAN motif are then phosphorylated by Plk4, enabling Sas6 recruitment.	Serine	15-22	polo like kinase 4	Homo sapiens	71-75
32908304-2	2020	Centrosomes themselves duplicate once per cell cycle, in a process that is controlled by the serine/threonine protein kinase PLK4 (refs.	Serine	93-99	polo like kinase 4	Homo sapiens	125-129
32807875-0	2020	FAM46C/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity.	tent5c	7-13	polo like kinase 4	Homo sapiens	68-72
32807875-1	2020	Polo like kinase 4 (Plk4) is a tightly regulated serine threonine kinase that governs centriole duplication.	Serine	49-55	polo like kinase 4	Homo sapiens	0-18
32807875-1	2020	Polo like kinase 4 (Plk4) is a tightly regulated serine threonine kinase that governs centriole duplication.	Serine	49-55	polo like kinase 4	Homo sapiens	20-24
32807875-4	2020	Herein we demonstrate physical interaction of Plk4 with FAM46C/TENT5C, a conserved protein of unknown function until recently.	tent5c	63-69	polo like kinase 4	Homo sapiens	46-50
32884289-9	2020	Furthermore, PLK4 was observed to be highly expressed in NSCLC tissues and cells, and PLK4 overexpression abolished the inhibitory effects of miR-654-3p overexpression on NSCLC cell proliferation.	mir-654-3p	142-152	polo like kinase 4	Homo sapiens	13-17
32884289-9	2020	Furthermore, PLK4 was observed to be highly expressed in NSCLC tissues and cells, and PLK4 overexpression abolished the inhibitory effects of miR-654-3p overexpression on NSCLC cell proliferation.	mir-654-3p	142-152	polo like kinase 4	Homo sapiens	86-90
32243714-0	2020	A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence.	talazoparib	36-47	polo like kinase 4	Homo sapiens	15-19
32536824-7	2020	The interaction between miR-338-3p and SNHG16 or PLK4 was confirmed by dual-luciferase reporter and RNA immunoprecipitation assay.	mir-338-3p	24-34	polo like kinase 4	Homo sapiens	49-53
32269206-4	2020	Centrinone, a reversible and selective PLK4 (polo-like kinase 4) inhibitor, has recently emerged as an efficient approach to eliminate centrosomes.	centrinone	0-10	polo like kinase 4	Homo sapiens	39-43
32269206-4	2020	Centrinone, a reversible and selective PLK4 (polo-like kinase 4) inhibitor, has recently emerged as an efficient approach to eliminate centrosomes.	centrinone	0-10	polo like kinase 4	Homo sapiens	45-63
32501498-0	2020	Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.	centrinone	47-57	polo like kinase 4	Homo sapiens	11-29
32501498-0	2020	Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.	centrinone	47-57	polo like kinase 4	Homo sapiens	31-35
32501498-3	2020	Recently, PLK4 has been targeted with a variety of small molecule kinase inhibitors exemplified by centrinone, which rapidly induces inhibitory effects on PLK4 and leads to on-target centrosome depletion.	centrinone	99-109	polo like kinase 4	Homo sapiens	10-14
32501498-3	2020	Recently, PLK4 has been targeted with a variety of small molecule kinase inhibitors exemplified by centrinone, which rapidly induces inhibitory effects on PLK4 and leads to on-target centrosome depletion.	centrinone	99-109	polo like kinase 4	Homo sapiens	155-159
32501498-5	2020	We report an unbiased mass spectrometry (MS)-based quantitative analysis of cellular protein phosphorylation in stable PLK4-expressing U2OS human cells exposed to centrinone.	centrinone	163-173	polo like kinase 4	Homo sapiens	119-123
32501498-8	2020	Surprisingly, sequence interrogation of ~300 significantly down-regulated phosphoproteins reveals an extensive network of centrinone-sensitive [Ser/Thr]Pro phosphorylation sequence motifs, which based on our analysis might be either direct or indirect targets of PLK4.	centrinone	122-132	polo like kinase 4	Homo sapiens	263-267
32501498-8	2020	Surprisingly, sequence interrogation of ~300 significantly down-regulated phosphoproteins reveals an extensive network of centrinone-sensitive [Ser/Thr]Pro phosphorylation sequence motifs, which based on our analysis might be either direct or indirect targets of PLK4.	Serine	144-147	polo like kinase 4	Homo sapiens	263-267
32501498-8	2020	Surprisingly, sequence interrogation of ~300 significantly down-regulated phosphoproteins reveals an extensive network of centrinone-sensitive [Ser/Thr]Pro phosphorylation sequence motifs, which based on our analysis might be either direct or indirect targets of PLK4.	Threonine	148-151	polo like kinase 4	Homo sapiens	263-267
32501498-8	2020	Surprisingly, sequence interrogation of ~300 significantly down-regulated phosphoproteins reveals an extensive network of centrinone-sensitive [Ser/Thr]Pro phosphorylation sequence motifs, which based on our analysis might be either direct or indirect targets of PLK4.	Proline	152-155	polo like kinase 4	Homo sapiens	263-267
32519033-0	2020	YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.	ylz-f5	0-6	polo like kinase 4	Homo sapiens	16-34
32519033-4	2020	In the present study, we aimed to determine if YLZ-F5, a potent small-molecule inhibitor of PLK4, inhibits ovarian cancer cell growth.	ylz-f5	47-53	polo like kinase 4	Homo sapiens	92-96
32519033-8	2020	Moreover, YLZ-F5 caused aberrant in centriole duplication that was associated with the inhibition of PLK4 phosphorylation.	ylz-f5	10-16	polo like kinase 4	Homo sapiens	101-105
32243714-5	2020	Interestingly, talazoparib, a novel and highly potent poly-ADP-ribose polymerase 1/2 (PARP1/2) inhibitor, could increase lncRNA PLK4 expression in HepG2 cells.	talazoparib	15-26	polo like kinase 4	Homo sapiens	128-132
32243714-6	2020	Importantly, we showed that talazoparib-induced lncRNA PLK4 could function as a tumour suppressor gene by Yes-associated protein (YAP) inactivation and induction of cellular senescence to inhibit liver cancer cell viability and growth.	talazoparib	28-39	polo like kinase 4	Homo sapiens	55-59
32243714-7	2020	In summary, our findings reveal the molecular mechanism of talazoparib-induced anti-tumor effect, and suggest a potential clinical use of talazoparib-targeted lncRNA PLK4/YAP-dependent cellular senescence for the treatment of HCC.	talazoparib	59-70	polo like kinase 4	Homo sapiens	166-170
32243714-7	2020	In summary, our findings reveal the molecular mechanism of talazoparib-induced anti-tumor effect, and suggest a potential clinical use of talazoparib-targeted lncRNA PLK4/YAP-dependent cellular senescence for the treatment of HCC.	talazoparib	138-149	polo like kinase 4	Homo sapiens	166-170
31926341-1	2020	Polo-like kinase 4 (PLK4) is a member of the serine/threonine protein kinase family involved in cell-cycle regulation and cellular response to stresses.	cholecystokinin C-terminal flanking peptide	45-51	polo like kinase 4	Homo sapiens	0-18
32126150-0	2020	Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.	Bortezomib	59-69	polo like kinase 4	Homo sapiens	14-18
32126150-5	2020	In this study, we established a cell model of PLK4 knockdown and overexpression in LN-18, A172 and LN-229 cells and found that knockdown of PLK4 expression enhanced the anti-tumour effect of bortezomib.	Bortezomib	191-201	polo like kinase 4	Homo sapiens	140-144
31926341-1	2020	Polo-like kinase 4 (PLK4) is a member of the serine/threonine protein kinase family involved in cell-cycle regulation and cellular response to stresses.	glycyl-threonine	52-61	polo like kinase 4	Homo sapiens	0-18
31926341-1	2020	Polo-like kinase 4 (PLK4) is a member of the serine/threonine protein kinase family involved in cell-cycle regulation and cellular response to stresses.	glycyl-threonine	52-61	polo like kinase 4	Homo sapiens	20-24
31926341-1	2020	Polo-like kinase 4 (PLK4) is a member of the serine/threonine protein kinase family involved in cell-cycle regulation and cellular response to stresses.	cholecystokinin C-terminal flanking peptide	45-51	polo like kinase 4	Homo sapiens	20-24
31379469-1	2019	High population density and economic development attributing to the changes in water quality in Pa Sak River, Lopburi River, and Mekong River have attracted great attention.	Water	79-84	polo like kinase 4	Homo sapiens	99-102
31926341-4	2020	PLK4 expression was dramatically reduced under ER stress induced by brefeldin A (BFA), tunicamycin (TM), or thapsigargin (TG) and down regulation of PLK4 expression was dependent on activating transcription factor 6 (ATF6) and CCAAT/enhancer-binding proteinbeta (C/EBPbeta).	Brefeldin A	68-79	polo like kinase 4	Homo sapiens	0-4
31926341-4	2020	PLK4 expression was dramatically reduced under ER stress induced by brefeldin A (BFA), tunicamycin (TM), or thapsigargin (TG) and down regulation of PLK4 expression was dependent on activating transcription factor 6 (ATF6) and CCAAT/enhancer-binding proteinbeta (C/EBPbeta).	Brefeldin A	81-84	polo like kinase 4	Homo sapiens	0-4
31926341-4	2020	PLK4 expression was dramatically reduced under ER stress induced by brefeldin A (BFA), tunicamycin (TM), or thapsigargin (TG) and down regulation of PLK4 expression was dependent on activating transcription factor 6 (ATF6) and CCAAT/enhancer-binding proteinbeta (C/EBPbeta).	Tunicamycin	87-98	polo like kinase 4	Homo sapiens	0-4
31926341-4	2020	PLK4 expression was dramatically reduced under ER stress induced by brefeldin A (BFA), tunicamycin (TM), or thapsigargin (TG) and down regulation of PLK4 expression was dependent on activating transcription factor 6 (ATF6) and CCAAT/enhancer-binding proteinbeta (C/EBPbeta).	Tunicamycin	100-102	polo like kinase 4	Homo sapiens	0-4
31926341-4	2020	PLK4 expression was dramatically reduced under ER stress induced by brefeldin A (BFA), tunicamycin (TM), or thapsigargin (TG) and down regulation of PLK4 expression was dependent on activating transcription factor 6 (ATF6) and CCAAT/enhancer-binding proteinbeta (C/EBPbeta).	Thapsigargin	108-120	polo like kinase 4	Homo sapiens	0-4
31926341-4	2020	PLK4 expression was dramatically reduced under ER stress induced by brefeldin A (BFA), tunicamycin (TM), or thapsigargin (TG) and down regulation of PLK4 expression was dependent on activating transcription factor 6 (ATF6) and CCAAT/enhancer-binding proteinbeta (C/EBPbeta).	Thapsigargin	122-124	polo like kinase 4	Homo sapiens	0-4
31926341-5	2020	Luciferase activity analysis of the truncated PLK4 promoter indicated that region from -1343 to -1250 of the PLK4 promoter was sensitive to BFA or TG.	Brefeldin A	140-143	polo like kinase 4	Homo sapiens	46-50
31926341-5	2020	Luciferase activity analysis of the truncated PLK4 promoter indicated that region from -1343 to -1250 of the PLK4 promoter was sensitive to BFA or TG.	Brefeldin A	140-143	polo like kinase 4	Homo sapiens	109-113
31926341-5	2020	Luciferase activity analysis of the truncated PLK4 promoter indicated that region from -1343 to -1250 of the PLK4 promoter was sensitive to BFA or TG.	Thapsigargin	147-149	polo like kinase 4	Homo sapiens	46-50
31926341-5	2020	Luciferase activity analysis of the truncated PLK4 promoter indicated that region from -1343 to -1250 of the PLK4 promoter was sensitive to BFA or TG.	Thapsigargin	147-149	polo like kinase 4	Homo sapiens	109-113
31926341-10	2020	ATF6 may upregulate DNA-binding affinities after BFA treatment, via recruiting C/EBPbeta to the upstream promoter of PLK4.	Brefeldin A	49-52	polo like kinase 4	Homo sapiens	117-121
31672968-5	2019	Analyses of the crystal structure of a phospho-mimicking, condensation-proficient CPB mutant reveal that a disordered loop at the CPB PB2-tip region is critically required for Plk4 to generate condensates and induce procentriole assembly.	phosphorylleucylphenylalanine	39-46	polo like kinase 4	Homo sapiens	176-180
31492983-1	2019	PURPOSE: Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates centriole duplication.	Serine	40-46	polo like kinase 4	Homo sapiens	9-27
31492983-1	2019	PURPOSE: Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates centriole duplication.	Serine	40-46	polo like kinase 4	Homo sapiens	29-33
31035676-8	2019	(2) Centrinone and centrinone B are the most selective PLK4 inhibitors but they are the least likely to penetrate the brain.	centrinone	4-14	polo like kinase 4	Homo sapiens	55-59
31035676-8	2019	(2) Centrinone and centrinone B are the most selective PLK4 inhibitors but they are the least likely to penetrate the brain.	centrinone-B	19-31	polo like kinase 4	Homo sapiens	55-59
31035676-10	2019	In conclusion, a new selective PLK4 inhibitor with favorable physiochemical properties for optimal brain exposure can be beneficial for the treatment of EBT.	ebt	153-156	polo like kinase 4	Homo sapiens	31-35
30804208-3	2019	To identify additional proteins regulated by PLK4, we generated an RPE-1 human cell line with a genetically engineered "analog-sensitive" PLK4AS, which genetically encodes chemical sensitivity to competitive inhibition via a bulky ATP analog.	Adenosine Triphosphate	231-234	polo like kinase 4	Homo sapiens	45-49
30804208-3	2019	To identify additional proteins regulated by PLK4, we generated an RPE-1 human cell line with a genetically engineered "analog-sensitive" PLK4AS, which genetically encodes chemical sensitivity to competitive inhibition via a bulky ATP analog.	Adenosine Triphosphate	231-234	polo like kinase 4	Homo sapiens	138-144
30804208-6	2019	Among them, we confirmed Ser-78 in centrosomal protein 131 (CEP131, also known as AZI1) as a direct substrate of PLK4.	Serine	25-28	polo like kinase 4	Homo sapiens	113-117
29352113-11	2018	Animal experiments demonstrated that the downregulation of PLK4 in SK-N-BE(2) cells dramatically suppressed tumorigenesis and metastasis.	sk-n-be	67-74	polo like kinase 4	Homo sapiens	59-63
30804208-7	2019	Using immunofluorescence microscopy, we observed that although PLK4-mediated phosphorylation of Ser-78 is dispensable for CEP131 localization, ciliogenesis, and centriole duplication, it is essential for maintaining the integrity of centriolar satellites.	Serine	96-99	polo like kinase 4	Homo sapiens	63-67
30804208-10	2019	We conclude that PLK4 phosphorylates CEP131 at Ser-78 to maintain centriolar satellite integrity.	Serine	47-50	polo like kinase 4	Homo sapiens	17-21
30529153-0	2019	PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.	Temozolomide	25-37	polo like kinase 4	Homo sapiens	0-4
30529153-2	2019	Here, we show that PLK4 affects TMZ sensitivity by regulating the IKBKE/NF-kappaB axis.	Temozolomide	32-35	polo like kinase 4	Homo sapiens	19-23
30529153-5	2019	In GBM cells, TMZ sensitivity was decreased by ectopic expression of PLK4 and enhanced by depletion of PLK4.	Temozolomide	14-17	polo like kinase 4	Homo sapiens	69-73
30529153-5	2019	In GBM cells, TMZ sensitivity was decreased by ectopic expression of PLK4 and enhanced by depletion of PLK4.	Temozolomide	14-17	polo like kinase 4	Homo sapiens	103-107
30529153-8	2019	Notably, the PLK4 inhibitor CFI400945, which is currently in clinical trials, had a synergistic effect with TMZ, increasing TMZ sensitivity in xenografts from patient-derived primary GBMs.	2-(3-(4-((2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one	28-37	polo like kinase 4	Homo sapiens	13-17
30529153-8	2019	Notably, the PLK4 inhibitor CFI400945, which is currently in clinical trials, had a synergistic effect with TMZ, increasing TMZ sensitivity in xenografts from patient-derived primary GBMs.	Temozolomide	108-111	polo like kinase 4	Homo sapiens	13-17
30529153-8	2019	Notably, the PLK4 inhibitor CFI400945, which is currently in clinical trials, had a synergistic effect with TMZ, increasing TMZ sensitivity in xenografts from patient-derived primary GBMs.	Temozolomide	124-127	polo like kinase 4	Homo sapiens	13-17
29330283-7	2018	Interestingly, although PLK4 expression did not correlate with CA in most cases, treatment of melanoma cells with a selective small-molecule PLK4 inhibitor (centrinone B) significantly decreased cell proliferation.	centrinone-B	157-169	polo like kinase 4	Homo sapiens	141-145
29330283-8	2018	The antiproliferative effects of centrinone B were also accompanied by induction of apoptosis.Implications: This study demonstrates that centriole overduplication is the predominant mechanism leading to centrosome amplification in melanoma and that PLK4 should be further evaluated as a potential therapeutic target for melanoma treatment.	centrinone-B	33-45	polo like kinase 4	Homo sapiens	249-253
30337519-0	2018	YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.	YLT-11	0-6	polo like kinase 4	Homo sapiens	16-20
30337519-7	2018	Meanwhile, cells treated with YLT-11 exhibited effects consistent with PLK4 kinase inhibition, including dysregulated centriole duplication and mitotic defects, sequentially making tumor cells more vulnerable to chemotherapy.	YLT-11	30-36	polo like kinase 4	Homo sapiens	71-75
27731453-8	2016	Based on KinView comparisons, we identify and experimentally characterize a regulatory tyrosine (Y177PLK4) in the PLK4 C-terminal activation segment region termed the P+1 loop.	Tyrosine	87-95	polo like kinase 4	Homo sapiens	101-105
28398638-11	2017	The PLK4 inhibitor CFI-400945 showed cytotoxic effects on rhabdoid tumor cell lines while sparing non-neoplastic human fibroblasts and developing zebrafish larvae.	2-(3-(4-((2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one	19-29	polo like kinase 4	Homo sapiens	4-8
29263250-10	2017	Thus the initiation of procentriole formation requires Plk4 to first phosphorylate a single serine residue in the ANST motif to promote Ana2"s recruitment and, secondly, to phosphorylate four residues in the STAN motif enabling Ana2 to recruit Sas6.	Serine	92-98	polo like kinase 4	Homo sapiens	55-59
21725316-7	2011	The activity of SCF-FBXW5 is in turn negatively regulated by Polo-like kinase 4 (PLK4), which phosphorylates FBXW5 at Ser 151 to suppress its ability to ubiquitylate HsSAS-6.	Serine	118-121	polo like kinase 4	Homo sapiens	61-79
27592744-0	2016	Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3"-indolin]-2"-ones as potent PLK4 inhibitors with oral antitumor efficacy.	(3-aryl-1h-indazol-6-yl)spiro[cyclopropane-1,3"-indolin]-2"-ones	27-91	polo like kinase 4	Homo sapiens	102-106
27592744-1	2016	Previous efforts from our laboratory demonstrated that (E)-3-((3-(E)-vinylaryl)-1H-indazol-6-yl)methylene)-indolin-2-ones are potent PLK4 inhibitors with in vivo anticancer efficacy upon IP dosing.	(e)-3-((3-(e)-vinylaryl)-1h-indazol-6-yl)methylene)-indolin-2-ones	55-121	polo like kinase 4	Homo sapiens	133-137
27061586-10	2016	The P-like pA+ biotype strains did not synthesize fibrinolysin, lacked the sak gene, and showed susceptibility to methicillin.	Protactinium	11-14	polo like kinase 4	Homo sapiens	75-78
26101219-3	2015	Here we used gene editing in human cells to create a chemical genetic system in which endogenous Plk4 can be specifically inhibited using a cell-permeable ATP analogue.	Adenosine Triphosphate	155-158	polo like kinase 4	Homo sapiens	97-101
25791677-3	2015	"Among spirooxindoles, CFI-400945, recently discovered by Sampson et al., is a potent PLK4 inhibitor, which has entered phase I clinical trials for the treatment of solid tumors.	spirooxindoles	7-21	polo like kinase 4	Homo sapiens	86-90
24389189-7	2014	In summary, it appears that Nek2 and Plk4 might synergize to promote breast tumorigenesis and may also be involved in tamoxifen and trastuzumab resistance.	Tamoxifen	118-127	polo like kinase 4	Homo sapiens	37-41
23829549-0	2013	The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.	(e)-3-((1h-indazol-6-yl)methylene)indolin-2-ones	34-82	polo like kinase 4	Homo sapiens	17-21
23829549-5	2013	Validated hits were used as starting points for the design and discovery of PLK4 inhibitors of novel structure, namely (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones.	(e)-3-((1h-indazol-6-yl)methylene)indolin-2-ones	119-167	polo like kinase 4	Homo sapiens	76-80
27326256-0	2016	Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy.	taxane	76-82	polo like kinase 4	Homo sapiens	33-37
27326256-4	2016	In addition, we immunohistochemically examined the changes of PLK4 expression in biopsy and postoperative tumor specimens of another 64 breast cancer patients who received taxane-based neoadjuvant chemotherapy.	taxane	172-178	polo like kinase 4	Homo sapiens	62-66
27326256-8	2016	Moreover, the results demonstrated that PLK4 expression was a negative predictor of response to taxane-based neoadjuvant chemotherapy (rs= - 0.253, P=0.044).	taxane	96-102	polo like kinase 4	Homo sapiens	40-44
27326256-9	2016	CONCLUSION: The findings of this current study indicated that PLK4 expression in breast cancer could be a potential prognostic factor and a negative predictor of response to taxane-based neoadjuvant chemotherapy.	taxane	174-180	polo like kinase 4	Homo sapiens	62-66
25931445-4	2015	To investigate the importance of centrosomes in the proliferation of normal and cancer cells, we developed centrinone, a reversible inhibitor of Polo-like kinase 4 (Plk4), a serine-threonine protein kinase that initiates centriole assembly.	centrinone	107-117	polo like kinase 4	Homo sapiens	145-163
25931445-4	2015	To investigate the importance of centrosomes in the proliferation of normal and cancer cells, we developed centrinone, a reversible inhibitor of Polo-like kinase 4 (Plk4), a serine-threonine protein kinase that initiates centriole assembly.	centrinone	107-117	polo like kinase 4	Homo sapiens	165-169
25174401-7	2015	Endogenous Plk4 phosphorylated at the autophosphorylation site S305 localizes to the protrusions of motile cells, coincident with the RhoA GEF Ect2, GTP-bound RhoA and the RhoA effector mDia.	3,3'-DIMETHOXYBENZIDINE DIHYDROCHLORIDE	63-67	polo like kinase 4	Homo sapiens	11-15
25174401-7	2015	Endogenous Plk4 phosphorylated at the autophosphorylation site S305 localizes to the protrusions of motile cells, coincident with the RhoA GEF Ect2, GTP-bound RhoA and the RhoA effector mDia.	Guanosine Triphosphate	149-152	polo like kinase 4	Homo sapiens	11-15
24867403-3	2015	Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3"-indolin]-2"-ones reported herein.	(e)-3-((1h-indazol-6-yl)methylene)indolin-2-ones	97-145	polo like kinase 4	Homo sapiens	52-56
24867403-3	2015	Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3"-indolin]-2"-ones reported herein.	2-(1h-indazol-6-yl)spiro[cyclopropane-1,3"-indolin]-2"-ones	188-247	polo like kinase 4	Homo sapiens	52-56
24867403-4	2015	Optimization of this new cyclopropane-linked series was based on a computational model of a PLK4 X-ray structure and SAR attained from the analogous alkenelinked series.	cyclopropane	25-37	polo like kinase 4	Homo sapiens	92-96
24867403-5	2015	The racemic cyclopropane-linked compounds showed PLK4 affinity and antiproliferative activity comparable to their alkene-linked congeners with improved hysicochemical, ADME, and pharmacokinetic properties.	cyclopropane	12-24	polo like kinase 4	Homo sapiens	49-53
21985771-6	2012	Remarkably, the Ser/Thr kinase PLK4 auto-phosphorylated on a tyrosine residue (Tyr177) located in the activation segment.	Tyrosine	61-69	polo like kinase 4	Homo sapiens	31-35
21725316-7	2011	The activity of SCF-FBXW5 is in turn negatively regulated by Polo-like kinase 4 (PLK4), which phosphorylates FBXW5 at Ser 151 to suppress its ability to ubiquitylate HsSAS-6.	Serine	118-121	polo like kinase 4	Homo sapiens	81-85
20392737-8	2010	Moreover, we observe extreme protein divergence amongst CBB components and show experimentally that there is loss of cross-species complementation among SAK/PLK4 family members, suggesting species-specific adaptations in CBB assembly.	coomassie Brilliant Blue	221-224	polo like kinase 4	Homo sapiens	157-161
20036743-0	2010	Deciphering the function of lactococcal phage ul36 Sak domains.	lactococcal	28-39	polo like kinase 4	Homo sapiens	51-54
17655330-5	2007	With respect to both substrate and ATP-site specificity, highest similarity is observed between PLK2 and PLK3, PLK1 is next most similar, and PLK4 is least similar.	Adenosine Triphosphate	35-38	polo like kinase 4	Homo sapiens	142-146
18656357-5	2008	One of these SSAPs was identified as Sak and was found in the virulent L. lactis phage ul36, which belongs to the Siphoviridae family [4, 5].	ssaps	13-18	polo like kinase 4	Homo sapiens	37-40
20032307-3	2010	Here, we show that PLK4 autophosphorylation of serine S305 is a consequence of kinase activation and enables the active fraction to be identified in the cell.	Serine	47-53	polo like kinase 4	Homo sapiens	19-23
17174311-5	2007	Using in vitro kinase assays on peptide spots arrays, we determined the consensus phosphorylation motif for Sak to be yen-[Ile/Leu/Val]-Ser/Thr-phi-phi-X- yen/Pro (where phi denotes a large hydrophobic residue, yen is a charged residue dependent on the context of the surrounding sequence, and residues in brackets are unfavoured).	Isoleucine	123-126	polo like kinase 4	Homo sapiens	108-111
17174311-5	2007	Using in vitro kinase assays on peptide spots arrays, we determined the consensus phosphorylation motif for Sak to be yen-[Ile/Leu/Val]-Ser/Thr-phi-phi-X- yen/Pro (where phi denotes a large hydrophobic residue, yen is a charged residue dependent on the context of the surrounding sequence, and residues in brackets are unfavoured).	Threonine	140-143	polo like kinase 4	Homo sapiens	108-111
17174311-5	2007	Using in vitro kinase assays on peptide spots arrays, we determined the consensus phosphorylation motif for Sak to be yen-[Ile/Leu/Val]-Ser/Thr-phi-phi-X- yen/Pro (where phi denotes a large hydrophobic residue, yen is a charged residue dependent on the context of the surrounding sequence, and residues in brackets are unfavoured).	Leucine	127-130	polo like kinase 4	Homo sapiens	108-111
17174311-5	2007	Using in vitro kinase assays on peptide spots arrays, we determined the consensus phosphorylation motif for Sak to be yen-[Ile/Leu/Val]-Ser/Thr-phi-phi-X- yen/Pro (where phi denotes a large hydrophobic residue, yen is a charged residue dependent on the context of the surrounding sequence, and residues in brackets are unfavoured).	Valine	131-134	polo like kinase 4	Homo sapiens	108-111
17174311-5	2007	Using in vitro kinase assays on peptide spots arrays, we determined the consensus phosphorylation motif for Sak to be yen-[Ile/Leu/Val]-Ser/Thr-phi-phi-X- yen/Pro (where phi denotes a large hydrophobic residue, yen is a charged residue dependent on the context of the surrounding sequence, and residues in brackets are unfavoured).	Serine	136-139	polo like kinase 4	Homo sapiens	108-111
11489907-7	2001	In human kidney 293 cells, Sak became tyrosine-phosphorylated by Tec, and the serine-threonine kinase activity of Sak was detected only under the presence of Tec, suggesting Sak to be an effector molecule of Tec.	Tyrosine	38-46	polo like kinase 4	Homo sapiens	27-30
12947367-3	2003	METHODS AND RESULTS: We evaluated patients with acute ST-elevation myocardial infarction within 6 hours of chest pain onset to determine a dose of PEG-Sak that had at least equal efficacy to recombinant tissue plasminogen activator (rt-PA) while maintaining an acceptable safety profile.	Polyethylene Glycols	147-150	polo like kinase 4	Homo sapiens	151-154
12947367-5	2003	Overall, 378 patients were studied across a PEG-Sak dose range from 0.01 mg/kg to 0.015 mg/kg, and 122 patients received accelerated rt-PA. At the lowest dose of PEG-Sak studied, 0.01 mg/kg, there was suggestive evidence of attenuation of efficacy; the point estimate for TIMI 3 flow was 24% (95% CI 9%-38%).	Polyethylene Glycols	162-165	polo like kinase 4	Homo sapiens	166-169
12947367-7	2003	CONCLUSION: The efficacy of PEG-Sak, coupled with its ease of administration, provide further impetus for further study in acute myocardial infarction.	Polyethylene Glycols	28-31	polo like kinase 4	Homo sapiens	32-35
16500616-2	2006	However, Dau attached to a polycationic polypeptide, poly[Lys(Seri-DL-Alam)] (SAK) exhibited no in vivo antitumor effect.	3-Deazauridine	9-12	polo like kinase 4	Homo sapiens	78-81
16500616-2	2006	However, Dau attached to a polycationic polypeptide, poly[Lys(Seri-DL-Alam)] (SAK) exhibited no in vivo antitumor effect.	poly[lys(seri-dl-alam)]	53-76	polo like kinase 4	Homo sapiens	78-81
15967108-6	2005	Significantly, p53-mediated SAK repression was largely reversed in a dose-dependent manner by Trichostatin A, a potent histone deacetylase (HDAC) inhibitor, suggesting an involvement of HDAC transcription repressors in SAK repression by p53.	trichostatin A	94-108	polo like kinase 4	Homo sapiens	28-31
15967108-6	2005	Significantly, p53-mediated SAK repression was largely reversed in a dose-dependent manner by Trichostatin A, a potent histone deacetylase (HDAC) inhibitor, suggesting an involvement of HDAC transcription repressors in SAK repression by p53.	trichostatin A	94-108	polo like kinase 4	Homo sapiens	219-222
11489907-7	2001	In human kidney 293 cells, Sak became tyrosine-phosphorylated by Tec, and the serine-threonine kinase activity of Sak was detected only under the presence of Tec, suggesting Sak to be an effector molecule of Tec.	Tyrosine	38-46	polo like kinase 4	Homo sapiens	114-117
11489907-7	2001	In human kidney 293 cells, Sak became tyrosine-phosphorylated by Tec, and the serine-threonine kinase activity of Sak was detected only under the presence of Tec, suggesting Sak to be an effector molecule of Tec.	Tyrosine	38-46	polo like kinase 4	Homo sapiens	114-117
34775733-1	2022	Background: Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase located in the centriole of the chromosome during the cell cycle.	Serine	43-49	polo like kinase 4	Homo sapiens	12-30
10639082-7	2000	We found that conjugates with polyanionic/EAK-[C(110-121)] or polycationic/SAK-[C(110-121)], AK-[C(110-121)]/character were capable to form monomolecular layers at the air/water interface with structure dependent stability in the following order: EAK-[C(110-121)] > SAK-[C(110-121)] > AK-[C(110-121)].	Water	172-177	polo like kinase 4	Homo sapiens	75-78
10639082-7	2000	We found that conjugates with polyanionic/EAK-[C(110-121)] or polycationic/SAK-[C(110-121)], AK-[C(110-121)]/character were capable to form monomolecular layers at the air/water interface with structure dependent stability in the following order: EAK-[C(110-121)] > SAK-[C(110-121)] > AK-[C(110-121)].	Water	172-177	polo like kinase 4	Homo sapiens	269-272
7863470-5	1994	Using 125I-labeled SAK/plg complex or SK/plg complex, the reaction of the complex with alpha 2-plasmin inhibitor was analyzed.	Iodine-125	6-10	polo like kinase 4	Homo sapiens	19-22
11093114-2	2001	CD spectra of polycationic (SAK, OAK), amphoteric (EAK), or polyanionic (Ac-EAK) polylysine derivatives were recorded in 0.25M acetate buffer at pH 7.4 as well as in the presence of DPPC or DPPC/PG (95/5, 80/20 mol/mol) liposomes.	Acetates	127-134	polo like kinase 4	Homo sapiens	28-31
34637843-6	2022	TEC directly phosphorylates PLK4 at tyrosine 86 residue, which not only stabilizes the protein but also enhances PLK4-mediated HCC cell invasion.	Tyrosine	36-44	polo like kinase 4	Homo sapiens	28-32
34775733-1	2022	Background: Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase located in the centriole of the chromosome during the cell cycle.	Serine	43-49	polo like kinase 4	Homo sapiens	32-36
34775733-7	2022	Immunohistochemistry for PLK4 in paraffin-embedded tissue was performed from the biopsy and surgical specimens.	Paraffin	33-41	polo like kinase 4	Homo sapiens	25-29
34672905-6	2021	Interestingly, increased TRIM37 protein levels sensitize cells to the PLK4 inhibitor centrinone.	centrinone	85-95	polo like kinase 4	Homo sapiens	70-74
35333404-9	2022	Moreover, PLK4 inhibitors CFI-400945 and centrinone-B inhibited cell growth, viability, and colony formation of both androgen-responsive and androgen-independent PCa cell lines.	centrinone-B	41-53	polo like kinase 4	Homo sapiens	10-14
34148296-7	2021	MM-PBSA calculations revealed the stability of hit molecules and PLK-4 complexes in comparison with CFI-400945 and the contribution to binding from key active site residues.	poly(tetramethylene succinate-co-tetramethylene adipate)	3-7	polo like kinase 4	Homo sapiens	65-70
34162828-4	2021	In this study, we discover that PLK4 is a potential target for the treatment of DLBCL, and demonstrate the efficacy of a PLK4 inhibitor when used in combination with doxorubicin.	Doxorubicin	166-177	polo like kinase 4	Homo sapiens	32-36
35508865-1	2022	OBJECTIVE: The anti-tumor effect of polo-like kinase 4 (PLK4) inhibitor has been explored in several neoplasms, while its synergy with bortezomib in multiple myeloma (MM) remains elusive.	Bortezomib	135-145	polo like kinase 4	Homo sapiens	36-54
35576702-0	2022	Design, synthesis, and biological evaluation of novel pyrazolo (3,4-d)pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.	pyrazolo(3,4-d)pyrimidine	54-80	polo like kinase 4	Homo sapiens	103-107
35576702-1	2022	Serine/threonine-protein kinase polo-like kinase 4 (PLK4) is a mitosis-associated protein kinase that plays a vital role in the duplication of centrioles in dividing cells and is considered a promising target of synthetic lethality in TRIM37-amplified breast cancer.	Serine	0-6	polo like kinase 4	Homo sapiens	52-56
35576702-2	2022	Herein, based on a rational drug design strategy, we described a series of pyrazolo (3,4-d)pyrimidine derivatives as potent PLK4 inhibitors and dissected the relevant structure-activity relationships (SARs).	pyrazolo(3,4-d)pyrimidine	75-101	polo like kinase 4	Homo sapiens	124-128
35508865-2	2022	Hence, the present study aimed to investigate the effect of PLK4 inhibitor on the sensitivity of MM to bortezomib treatment and its underlying mechanism.	Bortezomib	103-113	polo like kinase 4	Homo sapiens	60-64
35051862-9	2022	The activity of AURKB, but not AURKA or polo-like kinase 4, was diminished by corynoline.	corynoline	78-88	polo like kinase 4	Homo sapiens	40-58
35293662-0	2022	Hexavalent chromium induces centrosome amplification through ROS-ATF6-PLK4 pathway in colon cancer cells.	Chromium	11-19	polo like kinase 4	Homo sapiens	70-74
35293662-0	2022	Hexavalent chromium induces centrosome amplification through ROS-ATF6-PLK4 pathway in colon cancer cells.	Reactive Oxygen Species	61-64	polo like kinase 4	Homo sapiens	70-74
35293662-6	2022	Our results showed that a subtoxic concentration of chromium-induced CA in HCT116 colon cancer cells, resulted in the production of reactive oxygen species (ROS), activated ATF6 without causing endoplasmic reticulum stress, and upregulated the protein level of PLK4.	Chromium	52-60	polo like kinase 4	Homo sapiens	261-265
35293662-8	2022	Inhibition of ROS using N-acetyl-l-cysteine (NAC) inhibited chromium-induced activation of ATF6 and upregulation of PLK4.	Reactive Oxygen Species	14-17	polo like kinase 4	Homo sapiens	116-120
35293662-8	2022	Inhibition of ROS using N-acetyl-l-cysteine (NAC) inhibited chromium-induced activation of ATF6 and upregulation of PLK4.	Acetylcysteine	24-43	polo like kinase 4	Homo sapiens	116-120
35293662-8	2022	Inhibition of ROS using N-acetyl-l-cysteine (NAC) inhibited chromium-induced activation of ATF6 and upregulation of PLK4.	Acetylcysteine	45-48	polo like kinase 4	Homo sapiens	116-120
35293662-8	2022	Inhibition of ROS using N-acetyl-l-cysteine (NAC) inhibited chromium-induced activation of ATF6 and upregulation of PLK4.	Chromium	60-68	polo like kinase 4	Homo sapiens	116-120
35293662-11	2022	In conclusion, our results suggest that hexavalent chromium induces CA via the ROS-ATF6-PLK4 pathway and provides molecular targets for inhibiting chromium-mediated CA, which may be useful for the assessment of CA in chromium-promoted tumorigenesis and cancer cell metastasis.	Chromium	51-59	polo like kinase 4	Homo sapiens	88-92
35293662-11	2022	In conclusion, our results suggest that hexavalent chromium induces CA via the ROS-ATF6-PLK4 pathway and provides molecular targets for inhibiting chromium-mediated CA, which may be useful for the assessment of CA in chromium-promoted tumorigenesis and cancer cell metastasis.	Reactive Oxygen Species	79-82	polo like kinase 4	Homo sapiens	88-92